1. Pink Sheet
  2. >>Geography
  3. >>Asia
  4. >>China

In Brief

Valeant buys into Russian OTC market; NicOx buys stake in U.K. ophthalmology firm Altacor; Naturex reaches India coverage; Eurofins purchases BASF test business; Fortitech fortifies Asian presence; more news In Brief.

Natur Produkt International JSCis the latest consumer health acquisition for Valeant Pharmaceuticals International Inc., which announced its $180 million purchase of the Russian OTC company March 26. St. Petersburg-based Natur Produkt generated revenue of about $65 million in 2011 and is poised for double-digit growth in 2012, boosted by sales of the AntiGrippin cough/cold remedy brand Valeant said. The acquisition, which includes an additional $5 million in potential future milestone payments, is expected to close by mid-2012 and will be accretive immediately for Mississauga, Ontario-based Valeant. The Russian OTC market is proving attractive to pharma companies, including Johnson & Johnson Also see "J&J Expands Russian OTC Foothold Via J.B. Chemicals Portfolio Acquisition" - Pink Sheet, 30 May, 2011..

Nicox SA acquires 11.8% of privately held U.K. ophthalmology business Altacor Ltd. for £2 million ($3.2 million on...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

Expedited Reviews For China-Originated Drugs Shift Back Home

 
• By Xu Hu

The proportion of China-originated drugs granted expedited reviews in China doubled in the first half of this year, Pharmaprojects data show, surpassing those receiving similar treatment in the US and likely driven by multiple factors.

Beijing City Releases AI Action Plan Including Drug Regulation

 
• By Xu Hu

Amid the wait for an action plan to apply AI tools to drug regulation at the national level in China, capital city Beijing has released its own vision of scenarios for the technology in the healthcare sector.

China Unveils Multiple Policies To Support Innovative Drugs Throughout Life Cycle

 
• By Xu Hu

China has announced a raft of new measures to encourage innovative drug development across the product life cycle, including using insurance data to differentiate new therapies and applying commercial insurance to selected novel products.

To Compete With China, US FDA Must Deregulate Early Gene Therapy Studies, CAR-T Inventor Says

 
• By Sarah Karlin-Smith

FDA regulation was painted as an obstacle to US dominance in the cell and gene therapy space even as panelists at an agency event praised the Office of Therapeutic Products' track record under Nicole Verdun.

More from Asia

Expedited Reviews For China-Originated Drugs Shift Back Home

 
• By Xu Hu

The proportion of China-originated drugs granted expedited reviews in China doubled in the first half of this year, Pharmaprojects data show, surpassing those receiving similar treatment in the US and likely driven by multiple factors.

Australia Targets Clinical Trial Reform, AI Use And Drug Shortages In 12-Month Plan

 
• By Eliza Slawther

Reforming clinical trial regulations, addressing the use of artificial intelligence, mitigating medicines shortages and strengthening ties with other drug regulators are key priorities for Australia’s Therapeutic Goods Administration over the next year.

Leqembi Facing 15% Price Cut In Japan

 
• By Lisa Takagi

Japan looks set to press ahead with a reimbursement price cut for Eisai's Alzheimer's drug Leqembi following a cost-effectiveness review, despite differences with the company over methodology.